R&D News | pharmaphorum

News

AZ makes another cell therapy play with $1.2bn Gracell buy

AstraZeneca has lined up a $1.2 billion takeover deal for Chinese biotech Gracell Biotechnologies, bolting a series of cell therapies for cancer and autoimmune diseases on

News

A look back at 2023: Smith + Nephew

This year brought about a whole gambit of news and developments, of conferences and launches, all coming in thick and fast and excited about the pharmaceutical industry an

News

AI specialist Fauna grabs $494m Lilly obesity alliance

A US biotech that is trying to find new avenues for treating human diseases by studying the genomics of animal species, Fauna Bio, has agreed a deal with Eli Lilly focusin

News

Sanofi drops lung cancer ADC tusamitamab ravtansine

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung

News

GSK taps Hansoh for another cancer ADC candidate

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront

News

Argenx dealt another blow as Vyvgart Hytrulo fails again

Shares in Argenx have been taking a bashing this morning after the company announced its new subcutaneous formulation of Vyvgart had missed the mark in another phase 3 tri

AZ makes another cell therapy play with $1.2bn Gracell buy

A look back at 2023: Smith + Nephew

AI specialist Fauna grabs $494m Lilly obesity alliance

Sanofi drops lung cancer ADC tusamitamab ravtansine

GSK taps Hansoh for another cancer ADC candidate

Argenx dealt another blow as Vyvgart Hytrulo fails again

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks